Why the study?
Does the presence of pretransplant noncytotoxic HLA antibodies predict fatal and nonfatal adverse outcomes in heart transplant recipients?
Does the presence of pretransplant noncytotoxic HLA antibodies predict fatal and nonfatal adverse outcomes in heart transplant recipients?
Pretransplant noncytotoxic HLA antibodies detected by Luminex screening predict increased mortality, early graft failure, and rejection in heart transplant recipients.
Answers are grounded in this paper and cite their sources.
Pretransplant HLA antibodies were associated with doubled mortality after heart transplant; leaves open whether screening or desensitization improves outcomes.
HLA antibodies (HLA ab) in transplant candidates have been associated with poor outcome. However, clinical relevance of noncytotoxic antibodies after heart transplant (HT) is controversial. By using a Luminex-based HLA screening, we retested pretransplant sera from HT recipients testing negative for cytotoxic HLA ab and for prospective crossmatch. Out of the 173 consecutive patients assayed (52 ± 13y; 16% females; 47% ischemic etiology), 32 (18%) showed pretransplant HLA ab, and 12 (7%) tested positive against both class I and class II HLA. Recipients with any HLA ab had poorer survival than those without (65 ± 9 versus 82 ± 3%; P = 0.02), accounting for a doubled independent mortality risk (P = 0.04). In addition, HLA-ab detection was associated with increased prevalence of early graft failure (35 versus 15%; P = 0.05) and late cellular rejection (29 versus 11%; P = 0.03). Of the subgroup of 37 patients suspected for antibody mediated rejection (AMR), the 9 with pretransplant HLA ab were more likely to display pathological AMR grade 2 (P = 0.04). By an inexpensive, luminex-based, HLA-screening assay, we were able to detect non-cytotoxic HLA ab predicting fatal and nonfatal adverse outcomes after heart transplant. Allocation strategies and desensitization protocols need to be developed and prospectively tested in these patients.
No takes yet. Share an insight, caveat, or question.
Potena et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: